Cantor Fitzgerald Forecasts Weaker Earnings for Annexon

Annexon, Inc. (NASDAQ:ANNX) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Annexon in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of ($1.47) per share for the year, down from their prior estimate of ($0.99). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

Other analysts have also recently issued reports about the company. Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Annexon in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $15.80.

Annexon Stock Performance

Shares of ANNX stock opened at $2.76 on Thursday. Annexon has a 52-week low of $2.30 and a 52-week high of $8.40. The stock has a market cap of $294.20 million, a price-to-earnings ratio of -2.63 and a beta of 1.14. The firm’s 50-day moving average is $3.85 and its 200-day moving average is $5.38.

Annexon (NASDAQ:ANNX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05).

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. FMR LLC boosted its holdings in Annexon by 3.2% during the 3rd quarter. FMR LLC now owns 8,561,949 shares of the company’s stock valued at $50,687,000 after acquiring an additional 262,229 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of Annexon by 5.6% in the fourth quarter. Point72 Asset Management L.P. now owns 5,626,796 shares of the company’s stock worth $28,865,000 after buying an additional 299,798 shares in the last quarter. Vanguard Group Inc. increased its holdings in Annexon by 11.6% in the 4th quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company’s stock worth $28,456,000 after buying an additional 576,625 shares in the last quarter. State Street Corp raised its stake in Annexon by 116.6% during the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after buying an additional 2,068,294 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its holdings in shares of Annexon by 6.5% in the fourth quarter. Nuveen Asset Management LLC now owns 2,720,485 shares of the company’s stock worth $13,956,000 after buying an additional 164,915 shares during the last quarter.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.